

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Innovation . Verification . Development

IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

VOLUNTARY ANNOUNCEMENT

GLOBAL STRATEGIC COOPERATION FRAMEWORK ENTERED INTO WITH HASHKEY GROUP

This announcement is made by IVD Medical Holding Limited (the “**Company**” or “**IVD Medical**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the latest information on business developments of the Group.

The Board of Directors of the Company (the “**Board**”) is pleased to announce that, upon resolution of the Board, recently, the Company entered into a global strategic cooperation framework agreement (the “**Framework Agreement**”) with HashKey Group (“**HashKey Group**”), a leading global digital asset financial services group, with the aim of accelerating the implementation of the Group’s “global enhanced Ethereum (“**ETH**”) vault” strategy through close cooperation between the two parties and providing more efficient, secure, and compliant digital asset services to their global customers.

I. COOPERATION BACKGROUND AND STRATEGIC ALIGNMENT

IVD Medical is committed to the establishment of a global enhanced ETH vault. Through the two drivers of ETH reserves and the tokenization of innovative drug intellectual property rights (real world assets (“**RWA**”)), it aims to improve the efficiency of medical innovation drug research and development (“**R&D**”) and capital allocation, and provide global investors with a secure and efficient Web3 gateway. HashKey Group, as a leading global digital asset financial services group, has built a global Web3 ecosystem spanning Hong Kong in China, Singapore, Japan, Bermuda, and other regions within a compliant regulatory framework. Its business scope includes virtual asset trading, digital asset management, compliant over-the-counter transactions, and Web3 infrastructure services.

Pursuant to the Framework Agreement and subject to compliance with applicable laws and regulations and the Listing Rules of The Stock Exchange of Hong Kong Limited (“**Listing Rules**”), the cooperation will leverage HashKey Group’s fully licensed compliance ecosystem to provide the Group with one-stop digital asset management services, including but not limited to bulk transaction execution and cost optimization for ETH, global market liquidity support, and exploration of the integration approach between crypto asset reserves and real economy assets (especially the RWA of intellectual property rights of innovative drugs).

Through the cooperation with HashKey Group, the Group will be able to manage its ETH reserves more efficiently, optimize transaction costs, and gain access to broader market resources and technical support on a global scale.

II. COOPERATION CONTENT AND VALUE

(1) ETH Blockchain Trading Execution and Cost Optimization

HashKey Exchange and HashKey OTC, both subsidiaries of HashKey Group, will provide the Group with professional ETH blockchain trading execution services. Through HashKey Exchange’s compliant trading platform, the Group can execute large-scale ETH transactions at the most favorable prices. At the same time, the HashKey OTC’s over-the-counter trading services can further optimize transaction costs and ensure the security and compliance of transactions. HashKey Group’s trading execution capabilities will provide strong support for the Group’s ETH reserve management, reduce market volatility risks, and improve capital utilization efficiency.

(2) Global Market Liquidity Support

HashKey Group’s global trading platform, HashKey Global, will provide global market liquidity support for the Group’s ETH vault strategy. Through HashKey Global’s extensive network, the Group will be able to obtain sufficient liquidity on a global scale, ensuring the stable growth and efficient management of its ETH vault. Additionally, HashKey Global’s market insights and data analysis capabilities will provide the Group with real-time market information, helping the Group better capitalize on market opportunities and optimize investment decisions.

(3) Exploration of the Integration of Cryptocurrency Assets and Real Economy Assets

Both parties will jointly explore the approaches for integrating cryptocurrency reserves with real economy assets (particularly the RWA of intellectual property rights for innovative drugs). HashKey Group’s expertise in tokenization services will provide technical support and compliance guidance for the Group’s RWA projects, helping the Group convert innovative drug intellectual property into on-chain assets to achieve global circulation and maximize asset value. Through this collaboration, the Group will be able to further enhance the efficiency and funding support for innovative drug R&D, driving the global development of medical innovative drugs.

III. STRATEGIC SIGNIFICANCE AND FUTURE OUTLOOK

The strategic cooperation with HashKey Group marks an important step forward in the Group's strategic positioning in the global Web3 chain finance sector. Through the cooperation with HashKey Group, the Group will be able to fully leverage its world-leading digital asset financial services platform to accelerate the implementation of its "global enhanced ETH vault" strategy and provide global investors with more secure, efficient, and compliant digital asset services. Meanwhile, the collaboration between the two parties will also explore new approaches and methods for the tokenization and global circulation of intellectual property rights related to innovative drugs, thereby driving the R&D and commercialization of innovative drugs and contributing to the development of the global healthcare industry.

Looking ahead, the Group will continue to expand its collaboration with HashKey Group, actively exploring innovative cooperation methods to further enhance the Group's competitiveness and influence in the global Web3 sector. The Group believes that through close collaboration with HashKey Group, it will be able to create greater value for global investors, shareholders, and ecosystem participants, drive the sustainable development of the innovative pharmaceutical industry, and make a greater contribution to the health of mankind.

IV. STRATEGIC COOPERATION SIGNING CEREMONY AND GLOBAL STRATEGIC UPGRADE LAUNCH CONFERENCE

As one of the key events highlighting this strategic cooperation and in order to fully showcasing the value of our cooperation and strategic vision to the market, the Group and Hashkey will officially hold the "IVD-HashKey Global Strategic Cooperation Signing Ceremony and IVD Global Enhanced ETH Vault Strategic Upgrade Launch Conference" (the "**Conference**") from 2:00-4:30pm on Monday, 11 August 2025 in the office of Hashkey locating at Level 14, Three Exchange Square, Central, Hong Kong.

The conference will be held in a hybrid format combining both online and offline elements:

Offline conference: it will be held by invitation only, with distinguished guests including representatives from regulatory authorities, industry leaders, key partners, prominent institutional investors and creditworthy media journalists invited to attend in person to witness the commencement of the strategic partnership and upgrade launch of IVD Global Enhanced ETH Vault.

Online conference: To facilitate participation of a broad range of investors and people from all sectors, the conference will be simultaneously streamed through multiple professional financial and information platforms, including (but not limited to): Roadshowchina, Futubull, East Money APP, Jinmen Finance APP and Wind 3C Conference.

The Group believes that this conference not only formally announces the signing of the global strategic cooperation framework agreement between the two parties, but also an important opportunity to jointly advance the strategic upgrade of the Group's Global Enhanced ETH Vault, deepen market communication, demonstrate our determination to cooperate and future development path. The Company sincerely thank all parties for their continued attention and support for the Group and this strategic cooperation.

The Board of Directors hereby emphasises that the strategic cooperation may not necessarily proceed. The framework agreement is a framework agreement for strategic cooperation between the two parties, and specific matters will be further determined by the two parties when they enter into corresponding agreements in subsequent cooperation. Should the transactions contemplated under the Framework Agreement achieve substantial progress, the Company will, in accordance with the Listing Rules of the Hong Kong Stock Exchange, timely issue further announcements.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 8 August 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements are not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.

If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.